Apellis Pharmaceuticals competitors

Clive Richardson is a Board Member at Akari Therapeutics PLC. He has worked as Head:Operations at Volution Immuno Pharmaceuticals SA, Board Member at CLINISYS SOLUTIONS LIMITED, and Interim CEO/COO at Akari Therapeutics PLC. Clive works or has worked as Head:Equities Research at Investec. He attended Trinity College Oxford.

Mr Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He currently serves as the chairman of the American Kidney Fund board of trustees. The AKF is the leading patient focused charitable organization in kidney disease, providing assistance to one in 5 patients on kidney dialysis in the US. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.

Experienced Chief Executive Officer with a demonstrated history of working in the biotechnology industry. Skilled in Life Sciences Research & Development (R&D), Strategy, Financing, Business Development & Entrepreneurship.

Victor Perlroth co-founded Kodiak Sciences in 2009 and is the company’s Chairman and Chief Executive Officer. Together with a talented core team, he has built Kodiak on a foundation of scientific excellence with a simple mission—to design and develop novel medicines for highly prevalent diseases. Under Perlroth’s leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates. Previously, Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Perlroth co-founded Avidia, a biopharmaceuticals drug discovery and development company where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Perlroth was one of two principals involved in the acquisition of the company by Amgen for $450 million. Earlier, Perlroth worked at Guzik Technical Enterprises, the industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.

Craig Philips is the Interim Chief Executive Officer of Kv1.3 Therapeutics. He previously worked at Cell Therapeutics as a President. Craig Philips attended The Ohio State University.

Neil Kumar, Ph.D. has served as Eidos’ Chief Executive Officer and a member of its board of directors since March 2016. Neil Kumar founded BridgeBio Pharma, LLC and has served as its chief executive officer since September 2014. Prior to that, he served as the interim vice president of business development at MyoKardia, Inc. from 2012 to 2014. Prior to that, Neil Kumar served as a principal at Third Rock Ventures from 2011 to 2014. Before joining Third Rock, he served as an associate principal at McKinsey & Company from 2007 to 2011. He received his B.S. and M.S. degrees in chemical engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.